Anavex Life Sciences (AVXL) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic vision and therapeutic approach

• Focus on upstream intervention in CNS diseases by restoring autophagy, aiming to address root causes rather than downstream symptoms.

• Lead asset blarcamesine is a once-daily oral small molecule targeting sigma-1 activation to enhance autophagy and restore cellular homeostasis.

• Personalized, patient-oriented medicine is central, with a strong emphasis on convenience and quality of life for patients and caregivers.

• Significant market opportunity identified, with dementia cases projected to reach 130 million globally by 2050.

• Portfolio extends beyond Alzheimer's to Parkinson's, Rett syndrome, Fragile X syndrome, schizophrenia, and other rare CNS disorders.

Clinical data and efficacy

• Phase IIb/III trial of blarcamesine showed significant slowing of cognitive decline, with up to 49.8% benefit in a pre-specified population at 48 weeks.

• Demonstrated strong safety profile, no neuroimaging adverse events, and no deaths in trials, including long-term extension studies.

• Biomarkers such as brain volume loss and Aβ42 plasma ratio showed significant improvement.

• Quality of life measures improved above baseline for certain genetic groups, with sustained or net improvement after 48 weeks.

• Long-term extension study indicated up to 18 months of sustained patient benefit compared to standard of care.

Mechanism of action and precision medicine

• Blarcamesine activates sigma-1 receptors, restoring autophagy and reducing cellular stress, confirmed in vivo and in vitro.

• Efficacy is particularly strong in patients with wild-type sigma-1 and COL24A1 genes, representing a large portion of the population.

• Clinical benefit in the most homogeneous cohort reached 84.7% improvement over placebo in cognitive endpoints.

• Mechanism validated by PET studies and peer-reviewed publications, with dose-dependent sigma-1 engagement.

• Preventative effects observed in animal models, suggesting potential for early intervention.